Irbesartan And Hydrochlorothiazide Milpharm

Irbesartan, the active ingredient in Irbesartan And Hydrochlorothiazide Milpharm, is an Angiotensin II receptor blocker presented as a combination tablet for oral use. It is paired with hydrochlorothiazide, a thiazide diuretic, to manage hypertension in adult patients who need additional blood pressure control beyond monotherapy.

GNH USA supplies Irbesartan And Hydrochlorothiazide Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier, delivering EU‑origin quality products to hospitals, pharmacies and clinics worldwide through a regulated distribution network that ensures timely delivery and compliance with local regulations.

Irbesartan/Hydrochlorothiazide is used in the management of hypertension, acting on the renin‑angiotensin system and enhancing urinary sodium excretion. - Hypertension: lowers systolic and diastolic blood pressure by vasodilation and reduced plasma volume. - Resistant hypertension: provides additional blood pressure reduction when monotherapy with an ARB or diuretic is insufficient. - Cardiovascular risk reduction: helps decrease the risk of stroke and myocardial infarction associated with uncontrolled high blood pressure.

The combination may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Dizziness - Headache - Increased urination - Fatigue Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Allergic reactions such as rash or angioedema

When prescribing Irbesartan/Hydrochlorothiazide, clinicians should consider several safety measures to minimize risk. - Monitor blood pressure: ensure adequate control without excessive lowering. - Assess renal function: check serum creatinine and eGFR before and during therapy. - Check electrolytes: especially potassium and sodium levels regularly. - Use caution in patients with hepatic impairment: dose adjustment may be required. - Avoid in severe dehydration: may exacerbate hypotension and renal dysfunction. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Irbesartan/Hydrochlorothiazide can interact with other medicines, influencing efficacy or safety. Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment. - Dual therapy with ACE inhibitors or other ARBs: heightened risk of hyperkalemia and kidney injury. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia. Moderate Interactions (Monitor Closely): - Lithium: thiazide component may increase lithium levels, risking toxicity. - Other antihypertensives (beta‑blockers, calcium channel blockers): additive blood pressure lowering.